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the cumulative risk for a suicide attempt or completion over
the next year 10-fold and 100-fold, respectively.2 Self-report
is more sensitive for detecting suicidal ideation than clini-
cian interviews.3 Depressed residents, evaluated by the
HANDS inventory (Harvard Department of Psychiatry/
National Depression Screening Day Scale), make 6.2 times as
manymedicationerrorspermonth.4Underscoring the signifi-
cance of depression data from surveys, clinical guidelines ex-
plicitly support theiruse inassessingand treatingdepression.5
In the article, we provided a table of the sensitivities and
specificities of inventories included in the meta-analysis to
allow readers to judge the degree to which these estimates
reflected true MDD prevalence. We invite Levis and col-
leagues to apply these parameters to the instrument-specific
prevalence estimates in Figure 3 in the article, as doing so
demonstrates that MDD among residents is several-fold
higher than in the general population.
The methods used by some primary studies in our meta-
analysis have limitations. Future studies should incorporate
well-validated assessment tools, longitudinal follow-up, and
large sample sizes. This discussion, however, should not dis-
tract fromtheconclusion that residentdepressionanddepres-
sive symptoms are alarmingly high. The relevant question is
not whether they are high but rather why they are high. The
response to this questionwill havean important effect on resi-
dents and their patients.
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Treatment for PatientsWith Newly Diagnosed
Glioblastoma
To the Editor Dr Stupp and colleagues1 reported on the com-
bined use of temozolomide and tumor-treating fields
(TTFields) compared with temozolomide alone as adjuvant
therapy in patients with newly diagnosed glioblastoma. The
study of 315 patients demonstrated improvement in
progression-free survival (3.1 months) and overall survival
(4.9 months) in the TTFields-treated cohort (210 patients).
The question is whether this study, an interim analysis of the
total study population of 695 patients, is sufficiently compel-
ling to change current therapies for glioblastoma.
Barriers to use are manifold and include difficulty in use
of the device, cost of the device, the failure of TTFields for
recurrent glioblastoma, the potential palliative care effect
afforded by use of TTFields, and the uncertain exact mecha-
nism of action (as summarized in the accompanying
Editorial2). As the device is currently configured, patients
are required to shave their head twice per week, apply an
adhesive electrode array covering nearly the entire scalp,
and wear a 2.7-kg battery pack continuously for optimal
benefit.
The conspicuity of the TTFields device makes any
patient wearing it a subject of interest and curiosity. The
cost of the device is approximately $20000/mo. Because
the TTFields treatment requires an external portable device,
it is often not covered by insurers, potentially creating a sig-
nificant financial burden on the patient’s family. A previous
trial of patients with recurrent glioblastoma designed to
show superiority of TTFields compared with physician-
determined best therapy was negative.3
Whether involvement by the TTFields team (eg, assisting
in device set-up, familiarizing the family andpatientwith op-
eration of the device, providing replacement equipment, and
24/7 telephone access) contributes to survival benefit by
way of surrogate palliative care is unclear and a potential
confounder.4 Perhaps the greatest challenge to implementa-
tionofTTFields is acceptanceby theneuro-oncology commu-
nity (the clinicians primarily providing care for patients with
glioblastoma).
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In Reply Tumor-treating fields are a novel approach to the
treatment of cancer. In vitro and animal studies have dem-
onstrated that the use of alternating electrical fields, at a
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frequency specifically tuned to penetrate tumor cells,
interferes with microtubule formation, proper localization
of the cytokinetic contractile ring, and chromosomal segre-
gation, leading to cell cycle arrest, apoptosis, and reduced
clonogenic potential.1-3 Little progress has been made in
the treatment of glioblastoma over the last decade, yet
our study demonstrated a significant improvement in both
progression-free and overall survival in patients with
glioblastoma.
Dr Chamberlain suggests the results we found with
TTFields may be a placebo effect due to better palliative
care. Medical follow-up was identical in both treatment
groups. Although the patients treated with TTFields had
access to a 24-hour hotline, it was intended for possible
technical problems with the device. Once the first 2 to 3
weeks of treatment had passed, most patients became
independent with the device, and intervention by the tech-
nician was limited to 1 visit per month to supply new mate-
rials, record the use of the device, and solve any technical
problems.
The placebo effect is also thought to be anunlikely expla-
nation based on the results of 2 large randomized trials com-
paring intensified maintenance therapy with either dose-
dense temozolomide (21 d/mo vs 5 d/mo)4 or the addition of
cilengitide (requiring twice weekly visits to the chemo-
therapy suite for intravenous administration).5 Improvedout-
comes were not observed in either trial with the more inten-
sive treatment (hazardratios for survival, 1.03 [P = .63]and1.02
[P = .86], respectively).
Chamberlain points out that the device did not show su-
periority for recurrent disease6 (which also applies for most
other treatments used), thus contradicting the placebo hy-
pothesis. In the recurrent setting,TTFieldswasusedasa single
modality in very advanced disease, rather than in combina-
tion with chemotherapy in newly diagnosed patients.
We consider the difficulty in using the device to be quite
limited (the second-generation deviceweighs 1.3 kg), and the
electrodes are hidden easily beneath a cap or a wig. It is up to
the patient to decide whether the improvement in the 2-year
survival rate by 50% (from 29% to 43%) is worth it. The cost
of cancer treatments is a growing concern in all of oncology.
Thecosts, albeit substantial, are in the rangeofmanyothercan-
cer therapies.
Chamberlain speculated about resistance by the neuro-
oncology community to accept the results of the trial. It is dif-
ficult to explainwhy open and critical scientificmindswould
refuse to integratesoundclinical trial results intopractice, even
if the results were unexpected, especially when better alter-
natives are in short supply. Although the results were in-
terim, they were scrutinized for a best and worst case sce-
nario, and it is unlikely that the final results will show a
substantially different outcome.
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China’s One-Child Policy
To the Editor Dr Hesketh and colleagues1 provided a summary
and critique of China’s one-child policy, expressing skepti-
cism that eliminating this policy will cause fertility rates in
China to rebound. The authors delineated several positive
aspects of the one-child policy. However, those apparent
positives are mitigated by the corresponding costs associated
with them.
The first positive aspectwas the reductionof the total fer-
tility rate, its resulting prevention of 400 million births, and
the corresponding short-run demographic dividend. How-
ever, this is unlikely to create a demographic dividend in the
long run.2
The second positive aspect, the reduction of femalemor-
bidity andmortality risk from fewer pregnancies, overlooked
the morbidity and mortality risks associated with the lack of
family support and higher incidence of loneliness in the el-
derly that having only 1 child could exacerbate.
The third positive aspect was the acceleration toward
gender equality. How can a policy that resulted in the sex-
selective abortion of millions of girls simply because they
were identified as female, and that caused a gender imbal-
ance and a corresponding market for trafficking young
women, be viewed as accelerating a movement toward gen-
der equality? As China implements its two-child policy, it
remains to be seen whether the country will experience a
more rapid convergence toward gender balance and whether
other forms of child gender bias (unable to be manifested
within 1-child families) will replicate the bias that continued
to exist in the multichild households permitted by China.
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